Production of life saving medicines by M/s. Glaxo

550. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state-.

(a) the quantity ofseras and vaccines produced b 1980-81 and 1984-85;

(b) whether it is a fact that this company has drastically cut down the production of seras and vaccines and antibiotic vials during the last ten years;

(d) if so, what was the production of each of these items in 1975-76 and 1985-86; and

(d) what are the reasons for allowing M/s. Glaxo Laboratories to cut down the production of essential life saving medicines and to increase the production of non-essential formulations'

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (d) To the extent details are available M/s. Glaxo are producing triple Antisen. Production details, are as under: —

Year	Production (Ltrs.)
1976-77	N.A.
1980-81	1430
1984-85	1800

Production oi a product by a company depends upon the market demand and the corporate plans of the company. ' There had also not been any import of Triple Antigen.

Prices of Human Fibrtnogen

551. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 2109 given in the Rajya Sabha on the 17th March, 1986 and state;

(a) whether it is a fact that Human Fibrinogen, Hupaan Immulogichulin, Anti-Rho Immune Globulin (Human) are not reagents but are essential atnd life saving drugs;

(b) if so, whether it is also a fact that these products fall under Drug Price Control Order, 1979;

(c) what are the prices fixed for each of these products alongwith the date of fixation of price;

(d) whether it is also a fact that these life saving drugs are sold at an exhorbitant price; and

(e) if so, what are the reasons therefor?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (e) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

Agreement between M/s. Glaxo and Small Scale Units

552. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that M/s. Glaxo has entered into an agreement with small scale units to market for mulations produced by small scale units under their foreign brand names;

(b) if so, what are the detailed terms and period of each agreement;

(c) the names of small scale units with whom such agreement was made by M/s. Glaxo;

(d) whether Government treat such agreement legally tenable;

(e) the names of products being marketed by Glaxo which are produced by small scale units and whe-